These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 6232561)

  • 41. Increased macrophage migration inhibitory factor in Behçet's disease and relation with the disease activity.
    Serarslan G; Söğüt S; Yönden Z; Oksüz H; Savas N; Yenin JZ; Arpaci A
    J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1344-6. PubMed ID: 19368607
    [No Abstract]   [Full Text] [Related]  

  • 42. The relation between serum homocysteine level and eye involvement in Behçet's disease.
    Aflaki E; Mehryar M; Nazarinia MA; Habibagahi Z; Rajaee A; Ranjbar-Omrani G
    Arch Iran Med; 2008 Nov; 11(6):625-8. PubMed ID: 18976033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Behçet's disease.
    Evereklioglu C; Cekmen M; Ozkiriş A; Karabaş L; Caliş M
    Mediators Inflamm; 2003 Aug; 12(4):255-6. PubMed ID: 14514478
    [No Abstract]   [Full Text] [Related]  

  • 44. [Studies on immune interferon in Behçet's disease (author's transl)].
    Kato F; Ohno S; Fujii N; Minagawa T
    Nippon Ganka Gakkai Zasshi; 1981 Sep; 85(9):1412-9. PubMed ID: 6172968
    [No Abstract]   [Full Text] [Related]  

  • 45. Reduced erythrocyte deformability in active and untreated Behçet's disease patients.
    Tatlican S; Duran FS; Eren C; Eskioglu F; Dikmenoglu N; Oktay B; Durmazlar SP; Canpolat F
    Int J Dermatol; 2010 Feb; 49(2):167-71. PubMed ID: 20465640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High lipoprotein (a) levels as a thrombogenic risk factor in Behçet's disease.
    Orem A; Değer O; Memiş O; Calişkan K; Cimşit G
    Ann Rheum Dis; 1994 May; 53(5):351-2. PubMed ID: 8017992
    [No Abstract]   [Full Text] [Related]  

  • 47. [Behçet's disease--analysis of 20 patients].
    Mitrović D; Krstić S; Ivković L; Mićić R; Lilić D; Dujić A
    Srp Arh Celok Lek; 1985; 113(5-6):443-56. PubMed ID: 4089677
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum lipoprotein (a) levels in Behçet's disease.
    Seçkin D; Akpolat T; Oltulu Y; Erkan D; Cantürk T; Adam B; Turanli AY
    Br J Dermatol; 1995 Aug; 133(2):342-3. PubMed ID: 7547422
    [No Abstract]   [Full Text] [Related]  

  • 49. [Enhanced production of in vitro tumor necrosis factor-alpha from monocytes in Behçet's disease].
    Nakamura S; Sugita M; Tanaka S; Ohno S
    Nippon Ganka Gakkai Zasshi; 1992 Oct; 96(10):1282-5. PubMed ID: 1442353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Microtubules in polymorphonuclear leukocytes from patients with Behçet's disease].
    Saga T; Matsuda H
    Nippon Ganka Gakkai Zasshi; 1985 Feb; 89(2):349-53. PubMed ID: 4003214
    [No Abstract]   [Full Text] [Related]  

  • 51. Fractalkine (CX3CL1) levels in patients with Behçet's disease and neuro-Behçet's disease.
    Ceyla I; Tuba TK; Adisen E; Banu O; Isil F; Ali GM; Turgut I; Banu B
    J Neurol Sci; 2012 Apr; 315(1-2):120-2. PubMed ID: 22177089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibrinolysis and thrombosis in Behçet's disease.
    Sobel JD; Tabori S; Tatarski I
    Dermatologica; 1974; 148(2):93-7. PubMed ID: 4837654
    [No Abstract]   [Full Text] [Related]  

  • 53. Importance of serum amyloid-A in Behçet's disease.
    Agilli M; Aydin FN; Kurt YG; Cayci T
    Clin Rheumatol; 2016 Feb; 35(2):551-2. PubMed ID: 25586523
    [No Abstract]   [Full Text] [Related]  

  • 54. Plasma prostacyclin levels in Behçet's disease.
    Hizli N; Sahin G; Sahin F; Kansu E; Duru S; Karacadag S; Batman F; Dundar S; Zileli T; Telatar H
    Lancet; 1985 Jun; 1(8443):1454. PubMed ID: 2861400
    [No Abstract]   [Full Text] [Related]  

  • 55. Arachidonic acid metabolites in Behçet's disease.
    Bozkurt M; Gürer MA; Gülekon A; Keskin N; Ercan S
    Int J Dermatol; 1989 Mar; 28(2):141-2. PubMed ID: 2737813
    [No Abstract]   [Full Text] [Related]  

  • 56. Interleukin-15 and its receptor (IL-15Rα) serve as new therapeutic implications for Behçet's disease.
    He Y; Huang C; Wu BM; Li J
    Rheumatol Int; 2014 Aug; 34(8):1173-4. PubMed ID: 24046145
    [No Abstract]   [Full Text] [Related]  

  • 57. [Presence of a circulating anticoagulant during P. falciparum malaria].
    Hovette P; Berets O; Bernard F; Nizou JY
    Presse Med; 1994 Jul 2-9; 23(25):1179. PubMed ID: 7971851
    [No Abstract]   [Full Text] [Related]  

  • 58. Behçet's syndrome and factor XII deficiency.
    Disdier P; Harle JR; Mouly A; Aillaud MF; Weiller PJ
    Clin Rheumatol; 1992 Sep; 11(3):422-3. PubMed ID: 1458795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Behcet's disease with circulating anticoagulant].
    Pedinielli FJ; Taillan B; Blanc AP; Medvedowsky JL; Juan-Vague I; Jauffret P
    Presse Med; 1984 Apr; 13(18):1157. PubMed ID: 6232561
    [No Abstract]   [Full Text] [Related]  

  • 60. [Behçet's disease and lupus anticoagulant].
    Torrelo Fernández A; España Alonso A; Medina Montalvo S; Ledo Pozueta A
    Rev Clin Esp; 1990; 187(3):153. PubMed ID: 2126636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.